medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2006, Número 1

<< Anterior Siguiente >>

Neumol Cir Torax 2006; 65 (1)


Trasplante pulmonar

Chavarría MU, Posadas VR

Idioma: Español
Referencias bibliográficas: 71
Paginas: 11-23
Archivo PDF: 168.16 Kb.


RESUMEN

El trasplante pulmonar se ha consolidado como una alternativa real y efectiva en el tratamiento de la enfermedad pulmonar terminal. Esta revisión analiza la secuencia de eventos del trasplante: La evaluación del potencial candidato, el evento quirúrgico, el manejo inmediato postoperatorio y el seguimiento para detectar las complicaciones más importantes como la infección y el rechazo. Además, se discuten resultados fisiológicos de pacientes trasplantados en México.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hardy JD, Webb WR, Dalton ML, et al. Homotransplantation in man. JAMA 1963; 186: 1065-1074.

  2. Toronto Lung Transplantation Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986; 314: 1140-1145.

  3. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Lung and Heart–Lung Transplant Report-2005. J Heart Lung Transplant 2005; 24: 945-982.

  4. International Guidelines for the Selection of Lung Transplant Candidates. Am J Respir Crit Care Med 1998; 158: 335-339.

  5. Grupo de Trabajo de la SEPAR. Trasplante pulmonar. Arch Bronconeumol 2001; 37: 307-315.

  6. Glanville AR, Estenne M. Indications, patient selection and timing of referral for lung transplantation. Eur Respir J 2003; 22: 845-852.

  7. Kerem E, Reisman J, Corey M, Canny GT, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-1191.

  8. Doershuk CF, Stern RC. Timing of referral for lung transplantation for cystic fibrosis. Overemphasis on FEV1 may adversely affect overall survival. Chest 1999; 115: 782-787.

  9. Yankaskas JR, Mallory GB, and the Consensus Committee. Lung transplantation in cystic fibrosis. Consensus Conference Statement. Chest 1998; 113: 217-226.

  10. Aurora P, Whitehead B, Wade A, Bowyer J, Whitmore P, Rees PG, et al. Lung transplantation and life extension in children with cystic fibrosis. Lancet 1999; 354: 1591-1593.

  11. Meier-Sydow J, Weiss SM, Buhl R, Rust M, Raghu G. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15: 77-96.

  12. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for endstage lung disease. Lancet 1998; 351: 24-27.

  13. Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, Kotloff R, Morton J, Studer SM, Van Raemdonck D, Waddel T, Snell GI. A Review of Lung Transplant Donor Acceptability Criteria. The Journal of Heart and Lung Transplantation 2003; 22: 1183-1200.

  14. Garrity ER. Pre-transplant evaluation of the donor/organ procurement. In: Norman DJ, Suki WN, editors. Primer on Transplantation first edition. Thorofare, N.J. American Society of Transplant Physicians, 1998: 499-505.

  15. Myoshi S, Trulock EP, Shaefers H, Hsie C, Patterson GA, Cooper JD. Cardiopulmonary exercise testing after single and double lung transplantation. Chest 1990; 97: 1130-6.

  16. United Network for Organ Sharing. Guidelines for multiorgan donor management and procurement. UNOS Update 1993: 14-5.

  17. Harjula A, Baldwin JC, Starnes VA, et al. Proper donor selection for heart-lung transplantation. The Stanford experience. J Thorac Cardiovasc Surg 1987; 94: 874-80.

  18. Frost AE. Donor criteria and evaluation. Clin Chest Med 1997; 18: 231-7.

  19. Cooper JD. The lung donor: special considerations. Transplant Proc 1988; 20: 17-8.

  20. Griffith BP, Zenati M. The pulmonary donor. Clin Chest Med 1990; 11: 217-26.

  21. Winton TL, Miller JD, Scavuzzo M, et al. Donor selection for pulmonary transplantation. Transplant Proc 1991; 23: 2472-4.

  22. Egan T. Selection and management of the lung donor. In: Patterson GA, Couraud L, eds. Current topics in general thoracic surgery. Amsterdam: Elsevier, 1995: 103-15.

  23. Egan T, Boychuk JE, Rosato K, et al. Whence the lungs? A study to assess suitability of donor lungs for transplantation. Transplantation 1992; 53: 420-2.

  24. Riou B, Guesde R, Jacquens Y, et al. Fiberoptic bronchoscopy in brain-dead organ donors. Am J Respir Crit Care Med 1994; 150: 558-60.

  25. Lillehei CW, Shamberger RC, Mayer JE, Burke RP, Koka BV, Arnold J, et al. Size disparity in pediatric lung transplantation. J Pediatr Surg 1994; 29: 1152-5.

  26. Massard G, Badier M, Guillot C, Reynaud M, Thomas P, Giudicelli R. Lung size matching for double lung transplantation based on the submammary thoracic perimeter. Accuracy and functional results. J Thorac Cardiovasc Surg 1993; 105: 9-14.

  27. Miyoshi S, Schaefers HJ, Trulock EP, Yamazaki F, Schreinemakers H, Patterson GA, et al. Donor selection for single and double lung transplantation. Chest size matching and other factors influencing post-transplantation vital capacity. Chest 1990; 98: 308-13.

  28. Park SJ, Houck J, Pifarre R, Sullivan H, Garrity ER, Kim SY, et al. Optimal size matching in single lung transplantation. J Heart Lung Transplant 1995; 14: 671-5.

  29. Hayden AM, Scarlett MV, Fox K. Relationship between donor/recipient lung size mismatch and functional outcome in single lung transplantation for COPD. J Transplant Coord 1996; 6: 155-8.

  30. Sundaresan S, Trachiotis GD, Aoe M, Patterson GA, Cooper JD. Donor lung procurement: assessment and operative technique. Ann Thorac Surg 1993; 56: 1409-13.

  31. Pierre AF, Sekine Y, Hutcheon M, Waddell TK, Keshavjee S. Marginal lung donors: a reassessment. J Thorac Cardiovasc Surg 2002; 123(3): 421-8.

  32. Harjula A, Baldwin JC, Starnes VA, et al. Proper donor selection for heart-lung transplantation. The Stanford experience. J Thorac Cardiovasc Surg 1987; 94: 874-80.

  33. Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation 1993; 56: 1418-22.

  34. Waller DA, Bennett MK, Corris PA, Dark JH. Donor acquired fat embolism causing primary organ failure after lung transplantation. Ann Thorac Surg 1995; 59: 1565-6.

  35. Nakhleh R, Higgins RS. Donor cerebral tissue pulmonary emboli in a functioning transplanted lung. Clin Transplant 1998; 12: 504-7.

  36. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19: 1199-204.

  37. Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion 1998; 38: 975-88.

  38. Starzl TE, Tzakis A, Makowka L, et al. The definition of ABO factors in transplantation: relation to other humoral antibody states. Transplant Proc 1987; 19: 4492-7.

  39. Hunt BJ, Yacoub M, Amin S, et al. Induction of red blood cell destruction by graft-derived antibodies after minor ABO-mismatched heart and lung transplantation. Transplantation 1988; 1988: 246-9.

  40. Ciulli F, Tamm M, Dennis CM, et al. Donor transmitted bacterial infection after lung transplantation. Transplant Proc 1993; 25: 1155.

  41. Matuschak GM. Optimizing ventilatory support of the potential organ donor during evolving brain death: Maximizing lung availability for transplantation. Crit Care Med 2006; 34(2): 548-9.

  42. de Perrot M, Weder W, Patterson GA, Keshavjee S. Strategies to increase limited donor resources. Eur Respir J 2004; 23: 477-482.

  43. Lau CL, Patterson GA, Palmer SM. Critical care aspects of lung transplantation. J Intensive Care Med. 2004; 19: 83-104.

  44. Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000; 120: 99-107.

  45. Davis RD, Trulock EP, Manley J, et al. Differences in early results after single lung transplantation. Ann Thorac Surg 1994; 58: 1327-1335.

  46. Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteenyear experience in lung transplantation for emphysema. Ann Thorac Surg 2002; 74: 1663-1669.

  47. Hadjiliadis D, Davis RD, Palmer SM. Is transplant operation important in determining post-transplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? Chest 2002; 122: 1168-1175.

  48. Starnes VA, Bowdish ME, Woo MS, Barbers RG, Schenkel FA, Horn MV, Pessotto R, Sievers EM, Baker CJ, Cohen RG, et al. A decade of living lobar lung transplantation: recipient outcomes. J Cardiovasc Surg (Torino) 2004; 127: 114-122.

  49. Ahya VN, Kawut SM. Noninfectious Pulmonary Complications After Lung Transplantation. Clin Chest Med 2005; 26: 613-622.

  50. Van Muylem A, Melot C, Antoine M, et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997; 52: 643-7.

  51. Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171(11): 1312-6.

  52. Estenne M, Cassart M, Poncelet P, et al. Volume of graft and native lung after single-lung transplantation for emphysema. Am J Respir Crit Care Med 1999; 159(2): 641- 5.

  53. Chhajed PN, Malouf MA, Tamm M, et al. Interventional bronchoscopy for the management of airway complications following lung transplantation. Chest 2001; 120(6): 1894-9.

  54. Whelan TPM, Hertz MI. Allograft Rejection After Lung Transplantation. Clin Chest Med 2005; 26: 599-612.

  55. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lungtransplant recipients. N Engl J Med 2006; 354(2): 141-50.

  56. PulminiqTM (cyclosporine, USP) Inhalation Solution (CyIS) Briefing Document for the Pulmonary Advisory Committee Meeting June 6, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4135B1_02_A-FDAPulminiq.pdf

  57. Vincenti F, Kirkman R, Light S. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165.

  58. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou J. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198.

  59. Choi JK, Kearns J, Palevsky HI, et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999; 160: 1015.

  60. Van Muylem A, Melot C, Antoine M, et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997; 52: 643-7.

  61. Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995; 152: 2037-43.

  62. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15: 1-15.

  63. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127: 1126-32.

  64. Cahill BC, O’Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15: 1130-7.

  65. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984; 86: 824- 9.

  66. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.

  67. Nathan SD, Barnett SD, Wohlrab J, et al. Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. J Heart Lung Transplant 2003; 22: 427-32.

  68. Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121- 5.

  69. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-8.

  70. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170: 1022-6.

  71. Kotloff RM, Ahya VN, Crawford SW. Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation. Am J Respir Crit Care Med 2004; 170: 22-48.




2020     |     www.medigraphic.com